YKYee Hyung Kim

Yee Hyung Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yee Hyung Kim has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Gee Young Suh

    Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    1 shared publication
  • Hojoong Kim

    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    1 shared publication
  • Jae Chol Choi

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung‐Ang University School of Medicine

    1 shared publication
  • Jae-Joon Yim

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    1 shared publication
  • Kwang Ha Yoo

    Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea

    1 shared publication
  • Kyeongman Jeon

    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea

    1 shared publication

Latest Publications

  • Poor correlation between tuberculin skin tests and interferon-γ assays in close contacts of patients with multidrug-resistant tuberculosis

    by Kyung-Wook Jo, Kyeongman Jeon, Young Ae Kang, Won-Jung Koh, Kyung Chan Kim, Yee Hyung Kim, Kwang Ha Yoo, Seung Heon Lee, Jae-Joon Yim, Sang Bong Choi, et al.


  • Open Access

    Treatment of isoniazid-resistant pulmonary tuberculosis

    by Yee Hyung Kim, Gee Young Suh, Man Pyo Chung, Hojoong Kim, O Jung Kwon, Seong Yong Lim, Si Young Lim, Won-Jung Koh

    Background: Although resistance to isoniazid (INH) is the most common form of drug resistance seen among Mycobacterium tuberculosis isolates, there have been few studies on the efficacy and optimal duration of treatment for patients with INH-resistant tuberculosis (TB). Methods: We evaluated retrospectively the treatment outcomes of 39 patients who were treated for INH-resistant pulmonary TB. The treatment regimens consisted of a 12-month regimen of rifampin (RIF) and ethambutol (EMB), with pyrazinamide (PZA) given during the first 2 months (2HREZ/10RE) (n = 21), a 9-month regimen of RIF and EMB with PZA during the first 2 months (2HREZ/7RE) (n = 5), and a 6-month regimen of RIF, EMB, and PZA (2HREZ/4REZ) (n = 13). After drug susceptibility testing confirmed the INH-resistance of the isolated M. tuberculosis strains, INH was discontinued for all the patients. Results: Among the 39 patients, treatment was successfully completed by 36 patients (92%). However, treatment failure occurred, and acquired resistance to other first-line drugs, such as RIF, developed in three patients (8%). Cavitary and bilateral extensive lesions were commonly found in the chest radiographs of the patients who exhibited treatment failure. Conclusion: These findings underline the seriousness of concerns regarding treatment failure and the development of multidrug-resistant TB in patients with INH-resistant TB following treatment with recommended regimens.